AP4 (Iclusig 45 mg)

Generic Name: ponatinib

Pill imprint AP4 has been identified as Iclusig 45 mg.

Iclusig is used in the treatment of acute lymphoblastic leukemia; chronic myelogenous leukemia and belongs to the drug classes BCR-ABL tyrosine kinase inhibitors, multikinase inhibitors, VEGF/VEGFR inhibitors. There is positive evidence of human fetal risk during pregnancy. Iclusig 45 mg is not subject to the Controlled Substances Act.

See also related documents.

Imprint Search

Images for AP4

Iclusig 45 mg AP4
Iclusig 45 mg AP4
Iclusig
Generic Name:
ponatinib
Imprint:
AP4
Strength:
45 mg
Color:
White
Shape:
Round
Availability:
Prescription only
Drug Class:
BCR-ABL tyrosine kinase inhibitors
Multikinase inhibitors
VEGF/VEGFR inhibitors
Pregnancy Category:
D - Positive evidence of risk
CSA Schedule:
N - Not a controlled drug
Manufacturer:
ARIAD Pharmaceuticals, Inc.

View Details Print Page

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2014 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.

Hide
(web1)